Just reported
From Stryker's results release of 29. Oktober 2026; its quarterly report has since been filed.
Actual
6,52B $
+7,6 % y/y
-1,0 % q/q
Guided
—
No guide given
Actual
1,96 $
-12 % y/y
-41 % q/q
Guided
—
No guide given
Actual
1,03B $
-8,9 % y/y
-38 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Die Umsatzanteile sind Schätzungen für nine months ended 2026-09-30 und keine Zahlen aus einem eingereichten Bericht.
Surgical instruments and navigation systems
Powered surgical tools and navigation equipment that help surgeons carry out procedures.
Endoscopy and communications equipment
Cameras and related equipment that let clinicians view inside the body, alongside systems that connect operating-room equipment.
Patient and emergency-care equipment
Hospital beds, patient-handling equipment, emergency monitors and defibrillators, intensive-care disposables, and clinician communication systems.
Minimally invasive vascular devices
Catheters and other devices used in minimally invasive treatment of stroke and venous blood clots.
Brain and cranial surgery products
Products for brain and open-skull surgery, including synthetic bone grafts and products used to treat spinal bone conditions.
Joint and trauma implants and robotic surgery systems
Hip, knee, shoulder, ankle and trauma implants, plus robotic systems and surgical tools used in these operations.
Stryker makes equipment used during operations and in hospital wards, including cameras, surgical instruments, beds, emergency devices and systems that help hospital staff communicate. It also makes minimally invasive devices to treat strokes and blood clots, plus implants and robotic systems used in joint replacement and trauma surgery. It sells mainly to doctors, hospitals and other healthcare facilities, both directly and through distributors.
Gebaut aus den eigenen Einreichungen von Stryker Corp. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
309,64 $-0,9 %Schluss 13. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 30. Oktober 2026
Stryker sells operating-room and hospital-care equipment and minimally invasive stroke and clot-treatment devices to hospitals and clinicians, alongside implants and robots for joint surgery.
The themes Stryker is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc131,6B $A+
EWEdwards Lifesciences Corporation61,6B $A+
GEHCGE Healthcare Technologies Inc.37,5B $A
GKOSGlaukos Corp14,5B $A
PENPenumbra, Inc12,7B $ARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now AEWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now AGEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now AGrade A+
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 41 Quartalen der Notenhistorie von Stryker Corp.. Die übrigen 39 reichen zurück bis Oktober 2016.
